A Nutra-Pharmaceuticals class drug developed by UK based Lycotec Ltd for the treatment of a bacterial infection has filed a patent application. The new drug molecules are of food origin present in the Mediterranean diet and safe to consume. This is a first drug for the treatment of a bacterial infection that causes the development of cardiovascular disease (CVD) and atherosclerosis in an individual. In atherosclerotic plaques of people with cardiovascular disease (CVD), researchers identified a number of viruses and bacteria during the last three decades. Infections due to these bacteria and viruses are the reasons for the bad condition of atherosclerosis and CVD.
In multiple clinical studies, administration of this oral drug for 4 weeks duration has reduced anti-chlamydia antibodies and blood markers of oxidative-inflammatory damage in 85 percent of the patients with cardiovascular disease with double-blind and placebo-controlled individuals. The manufacturer is going to present the drug and clinical trial results at CBRS Conference in Charlotte, NC, in April 2017. Lycotec company is currently looking for a funding deal with other pharma company. One of the inventors of this drug is Dr. Ivan Petyaev, founder of Lycotec. Co-author of this invention is Prof Nailya Zigangirova.
Type ii diabetes (T2D) patients in the UK got a new treatment option to control their blood sugar levels with the availability of FDA approved qtern drug from AstraZeneca. It is a fixed combination drug of 5 mg DPP-4 inhibitor (saxagliptin) and 10 mg SGLT2 inhibitor (dapagliflozin), to be used once in a day. The drug was approved by the European Union during July 2016 intended to improve glycemic control in type 2 diabetes patients when
The blood condition in an individual with high levels of triglycerides, fat phospholipids and LDL cholesterol is known as dyslipidemia. Dyslipidemia blood condition is associated with the huge costs (price) to manage complications due to type 2 diabetes (T2D) condition. On the average, an American individual is spending $13,700 to take care of diabetes condition, according to the ADA. Researchers from Kaiser Permanente, based in California, United States says medical costs can be reduced with triglyceride lowering therapy in type ii diabetes (T2D) patients. Researchers conducted observational studies among 184,000 type 2 diabetes patients. Researchers compared triglyceride levels and medical costs before and after treatment intended to lower cholesterol and triglyceride levels. Study results show
But researchers unable to say the economic saving is due to the treatments or due to a reduction in triglyceride levels. The study findings were published in the American Journal of Cardiology.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.